3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
473
Neoplasms
290
Breast Neoplasms
277
Colorectal Neoplasms
223
Neoplasm Metastasis
187
Prostatic Neoplasms
168
Ovarian Neoplasms
163
Lung Neoplasms
154
Multiple Myeloma
152
Recurrence
132
Melanoma
116
Pancreatic Neoplasms
114
Squamous Cell Carcinoma of Head and Neck
104
Endometrial Neoplasms
98
Stomach Neoplasms
97
Leukemia, Myeloid, Acute
95
Small Cell Lung Carcinoma
84
Leukemia, Lymphocytic, Chronic, B-Cell
83
Lymphoma, Non-Hodgkin
81
Triple Negative Breast Neoplasms
80
Carcinoma, Renal Cell
79
Carcinoma, Hepatocellular
77
Urinary Bladder Neoplasms
75
Lymphoma, Large B-Cell, Diffuse
72
Lymphoma, Follicular
64
Advanced Solid Tumors
63
Lymphoma
60
Glioblastoma
57
Parkinson Disease 4, Autosomal Dominant Lewy Body
55
Head and Neck Neoplasms
53
Interventions
tremelimumab
1
durvalumab
1
atezolizumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Unresectable Hepatocellular Carcinoma
×
90 days
×
Clear all
NCT06117891
2026-05-12
REFINE-IO
Bayer
Active not recruiting
300 enrolled